ED arrests man in Rs 3.75 crore psychotropic drug case

Published On 2025-12-17 11:15 GMT | Update On 2025-12-17 11:15 GMT

Directorate of Enforcement (ED), Jalandhar Zonal Office, has arrested an individual, for his involvement in generation and acquisition of proceeds of crime through illegal sale of psychotropic tablets such as Tramadol and Alprazolam under the provisions of the Prevention of Money Laundering Act (PMLA) 2002.

He was produced before the Hon’ble Special Court (PMLA), 2002, SAS Nagar, and the Special Court has granted six days ED custody of the accused.

ED initiated investigation on the basis of FIR registered by Punjab Police under various sections of NDPS Act 1985 relating to the large-scale inter-state trafficking of psychotropic tablets and capsules, particularly Tramadol and Alprazolam. Thereafter, a search action was conducted at 16 premises linked with Abhishek Kumar and other entities which resulted in seizure of various incriminating records.

ED investigation revealed that the middle men viz wholesalers and retailers were procuring huge quantities of psychotropic tablets from pharmaceutical firms/manufacturing companies, namely M/s Biogenetic Drugs Pvt. Ltd., M/s CB Healthcare, M/s Smilax Pharmachem Drug Industries, M/s Aster Pharma, M/s Soul Health Care (I) Pvt. Ltd, and were diverting it for sale in black market at high cost than the retail price, through drug peddlers, thereby generating huge Proceeds of Crime (POC).

Abhishek Kumar through his firm, M/s Shree Shyam Medical Agency, procured bulk quantities of these psychotropic tablets from wholesalers/manufacturers and illegally diverted/sold approximately 75% of the stock of these psychotropic tablets out of books. In order to conceal these illicit transactions, the corresponding boxes were shown as legal sales by inflating the number of boxes in the legal bills, thereby generating POC to the tune of Rs. 3.75 Crore in cash.

Read also: ED attaches Rs 2.58 crore assets in corruption case linked to Himachal Assistant Drug Controller

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

ED arrests man in Rs 3.75 crore psychotropic drug case

Similar News

Odisha launches Pharmaceutical and Medical Devices Policy 2025, eyes Rs 25000 cr investment

Lupin receives positive EMA comittee opinion for eye therapy Ranluspec

GSK twice yearly Exdensur secures USFDA approval for severe asthma

Biocon Biologics recognized as Asia IP Elite for 2025 by IAM

Lupin Nagpur injectable facility gets EIR from USFDA

Sun Pharma Asked to Resubmit Revised Phase III Protocol for Delafloxacin CABP Trial

Panacea Biotec appoints Vinod Goel as CFO